Evidence map›Paper›PMID 31410784›Full record

ArticleJournal of racial and ethnic health disparities2019

The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease.

Sarah M Jabour, Sara Beachy, Shayna Coburn, Sophie Lanzkron, Michelle N Eakin

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of racial and ethnic health disparities, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07540767 (Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07540767 nanot yet recruitingnot on this mapstarted 2027, after this paper: background citation

Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease

TypeinterventionalSponsorConnecticut Children's Medical CenterRan2027 to 2030Enrolled30ConditionsSickle Cell Disease, Sickle Cell Anemia in Children, Sickle Cell Disease (SCD), Sickle CellArmsIndividuation and Perspective-Taking (IPT), pediatric SCD pain management education session
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Review
  3. The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease.Mediterranean journal of hematology and infectious diseases · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Sarah M JabourDivision of General Internal Medicine, Johns Hopkins University, Baltimore, MD, USA.
Sara BeachyDepartment of Education and Health Services, Lehigh University, Bethlehem, PA, USA.
Shayna CoburnChildren's National Health System, Washington, D.C., USA.
Sophie LanzkronDivision of Hematology, Johns Hopkins University, Baltimore, MD, USA.
Michelle N EakinDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, 5501 Hopkins Bayview Blvd., Room 4B.74, Baltimore, MD, 21224, USA. meakin1@jhu.edu.
Johns Hopkins University · USChildren's National · USLehigh University · US

Funding

Improving Access to Hydroxyurea for Adults with Sickle Cell DiseaseR34HL113438 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI LANZKRON, SOPHIE M · 2013 to 2014
$706k
NHLBI NIH HHS R34 HL113438
6 · The paper itself

Abstract

objectiveThis qualitative study analyzed the perspective of patients living with sickle cell disease (SCD) on their process of deciding whether to take hydroxyurea (HU), and the role of physician communication in patients' decision-making process.

methodsFrom October 2015 to July 2016, we conducted semi-structured interviews among patients with SCD (N = 20) that were audio-recorded and transcribed. Participants were ≥ 18 years old, a patient of an urban adult sickle cell center, able to provide informed consent, and English-speaking. We iteratively developed codes and used thematic analysis to organize the key themes.

resultsMost participants were female (65%), middle aged (M = 44, SD = 12.2), and 55% were prescribed HU for an average of 10.4 (SD = 4.7) years. Participants described 3 key factors that influenced their decision regarding HU treatment: (1) lifestyle, (2) health status, and (3) HU characteristics. Four themes emerged about provider communication and HU treatment decisions: (1) provider's advisement, (2) shared decision-making, (3) "wrestled," and (4) not feeling heard.

conclusionProviders who engaged in shared decision-making empowered participants to decide whether to start HU treatment. Participants who felt their providers were not listening to their concerns expressed disengaging from HU treatment. During discussions about HU with patients living with SCD, providers must understand the multi-faceted aspects that impact patients' decision and empower patients to engage in such discussions. Further research is needed to understand the role of shared decision-making among patients with SCD to improve management of SCD.

Indexed as

CommunicationDecision Making, SharedPhysician-Patient RelationsAdultAnemia, Sickle CellAntisickling AgentsDecision MakingFemaleHealth Services AccessibilityHumansHydroxyureaMaleMiddle AgedQualitative ResearchAntisickling AgentsHydroxyureaPatient-provider communicationShared decision-making, hydroxyureaSickle cell disease

Identifiers

PMID31410784
PMCPMC6832819
OpenAlexW2967629285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.